Neurocrine Biosciences (NBIX) Tops Q3 EPS by 75c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $164.85 --0%
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.97, $0.75 better than the analyst estimate of $0.22. Revenue for the quarter came in at $258.5 million versus the consensus estimate of $283.04 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $224 at Guggenheim
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
- Neuronetics (STIM) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
